Shanghai Mental Health Center

Running trials

• Not yet recruiting

  iMORE+ Study: A Multi-Omics Cohort Study of Major Depressive Disorder

  NCT07735143· Shanghai Mental Health Center· Source

• Not yet recruiting

  Xingqi Daozhi Decoction for Antipsychotic-Induced Constipation

  NCT07767526· Phase 1/2· Shanghai Mental Health Center· Source

• Not yet recruiting

  Phase I Trial of HHK101 in Patients With Schizophrenia

  NCT07815210· Phase 1· Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.· Source

• Not yet recruiting

  Phase 3 Study of HS-10380 for Acute Schizophrenia in Chinese Adults

  NCT07911787· Phase 3· Jiangsu Hansoh Pharmaceutical Co., Ltd.· Source

• Not yet recruiting

  A Multicenter Observational Study of Daridorexant in the Treatment of Insomnia

  NCT07847021· Shanghai Mental Health Center· Source

• Not yet recruiting

  Multi-target TMS for Schizophrenia Negative Symptoms

  NCT07559084· Shanghai Mental Health Center· Source

• Recruiting

  Sequential Treatment Approaches for Treatment-Resistant Schizophrenia

  NCT07918222· Phase 3· Shanghai Mental Health Center· Source

• Not yet recruiting

  Home-Based Wearable rTMS Therapy for Moderate to Severe Depression

  NCT07775586· Shanghai Mental Health Center· Source

• Not yet recruiting

  Probiotic IBNI617 for Moderate to Severe Depression

  NCT07728253· IBIOME BIOTECHNOLOGY CO., LTD· Source

• Not yet recruiting

  Tracking Risk in Adolescents and Children for Early Identification of Common Mental Disorders

  NCT07744490· Shanghai Mental Health Center· Source

• Not yet recruiting

  Efficacy and Mechanisms of TUS on Cognitive Deficits in Schizophrenia: Based on the Hippocampal-Prefrontal Circuit

  NCT06904092· Shanghai Mental Health Center· Source

• Not yet recruiting

  Study of Neural Stem Cell-Derived Exosomes in Moderate-to-Severe Early-Onset Alzheimer's Disease

  NCT07554872· Phase 1· Shanghai Mental Health Center· Source

• Recruiting

  A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

  NCT07573176· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  The Effect of Game-Based Intervention on the Cognition of Schizophrenia Patients

  NCT07557381· Shanghai Mental Health Center· Source

• Recruiting

  Effects of Gamified Rehabilitation on Cognitive and Psychosocial Outcomes in Inpatients With Schizophrenia

  NCT07557368· Shanghai Mental Health Center· Source

• Recruiting

  Identification and Molecular Characterisation of Urban-environmental Stress Patterns Affecting Mental Illness

  NCT07571226· Huashan Hospital· Source

• Recruiting

  An Exploratory Study on the Prediction of Recurrence Risk of Bipolar Disorder Using Sentiment Analysis Technology Based on Multi-modal Feature Fusion

  NCT07573839· Shanghai Mental Health Center· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Major Depressive Disorder

  NCT07412756· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Multicenter Observational Study of Lemborexant on Insomnia Patients With Psychiatric Disorders

  NCT07417813· Shanghai Mental Health Center· Source

• Not yet recruiting

  First-In-Human (FIH), Single Ascending Dose (SAD) Study and Multiple Ascending Dose (MAD) Study of SP-101 Injection

  NCT07334249· Phase 1· Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.· Source

• Recruiting

  Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)

  NCT07262645· Phase 3· Danyang Huichuang Medical Equipment Co., Ltd.· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

  NCT07286175· Phase 2· Eli Lilly and Company· Source

• Active, not recruiting

  Clinical Study of Compound Ciwujia Granules in the Treatment of Depression

  NCT07085143· Phase 4· Shanghai Mental Health Center· Source

• Enrolling by invitation

  Investigation on Risk Factors for Suicide Among Chinese Patients With Mood Disorders

  NCT07281729· Shanghai Mental Health Center· Source

• Not yet recruiting

  A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017

  NCT06980207· Phase 1· Luye Pharma Group Ltd.· Source

• Recruiting

  Lecanemab for Early Onset Familial Alzheimer's Disease

  NCT06883019· RenJi Hospital· Source

• Recruiting

  RTMS for Refractory Auditory Hallucinations Based on Personalized Targets Using Magnetoencephalography

  NCT06802939· Shanghai Mental Health Center· Source

• Not yet recruiting

  Effect of Food and Age on the Pharmacokinetics of LY03017

  NCT06793995· Phase 1· Luye Pharma Group Ltd.· Source

• Recruiting

  Model-Driven Individualized Transcranial Direct Current Stimulation for the Treatment of Insomnia Disorders

  NCT06671457· Zhen Wang· Source

• Recruiting

  A Cohort Study of Disease Prediction Model for High-risk Population With Bipolar Disorder

  NCT07031661· Shanghai Mental Health Center· Source

• Recruiting

  A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Recruiting

  Magnetic Seizure Therapy for Psychotic Disorders

  NCT06581302· Shanghai Jiao Tong University School of Medicine· Source

• Recruiting

  Effectiveness of MST Versus ECT for Major Depressive Episode

  NCT06409325· Shanghai Mental Health Center· Source

• Recruiting

  Efficacy of Hi-tACS for Schizophrenia Negative Symptoms

  NCT06888726· Shanghai Mental Health Center· Source

• Recruiting

  Prediction and Intervention Effect of Rehabilitation Status for Severe Mental Disorder Patients Based on Multimodal Analysis and AI Agents

  NCT06904079· Shanghai Mental Health Center· Source

• Recruiting

  Mechanisms of Response to Therapeutic Intervention in Clinical High Risk (CHR) for Psychosis

  NCT06542640· Beth Israel Deaconess Medical Center· Source

• Recruiting

  Efficacy and Safety of Combo-stim Deep Brain Stimulation for Treatment-refractory Mental Disorders

  NCT06112067· Shanghai Mental Health Center· Source

• Recruiting

  Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Recruiting

  Non-invasive BCI and Application Verification for Depressed People

  NCT06417437· Phase 4· Shanghai Mental Health Center· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

  NCT05508789· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Long-term Efficacy and Safety Study of GV-971

  NCT05181475· Phase 4· Green Valley (Shanghai) Pharmaceuticals Co., Ltd.· Source

• Recruiting

  Mental Health During the Whole Life Cycle of Community Patients With Schizophrenia

  NCT05159349· Shanghai Mental Health Center· Source

• Recruiting

  An Observational Study on Atypical Antipsychotics Long-term Treatment Patients With Schizophrenia

  NCT02640911· Shanghai Mental Health Center· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Schizophrenia18 recruiting
• Depression11 recruiting
• Alzheimer disease7 recruiting
• Bipolar disorder6 recruiting
• Insomnia3 recruiting
• Parkinson disease2 recruiting
• Autism1 recruiting
• Epilepsy1 recruiting

Closed trials

• Completed

  Precise Intervention Technology and Application of Low Intensity TUS on Negative Symptoms of Schizophrenia

  NCT05985993· Shanghai Mental Health Center· Source

• Completed

  The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

  NCT06827431· Phase 3· CSPC ZhongQi Pharmaceutical Technology Co., Ltd.· Source

• Completed

  A Phase II Study to Evaluate NH102 for Depression

  NCT06842992· Phase 2· Jiangsu Nhwa Pharmaceutical Co., Ltd.· Source

• Completed

  Recombinant Human Serum Albumin in the Treatment of Mild-to-moderate AD (Alzheimer's Disease) Exploratory Clinical Trial

  NCT06489015· Early phase 1· Shenzhen Protgen Co., Ltd.· Source

• Completed

  Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets

  NCT06474650· Phase 1· Luye Pharma Group Ltd.· Source

• Completed

  A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia

  NCT07550387· Phase 2· Jiangsu Hansoh Pharmaceutical Co., Ltd.· Source

• Withdrawn

  Targeted Intervention Study of DTMS on Impaired Insight in Early Psychosis

  NCT04513132· Shanghai Mental Health Center· Source

• Completed

  Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects

  NCT06216054· Phase 1· Luye Pharma Group Ltd.· Source

• Completed

  A Study of Daridorexant in Chinese Patients With Insomnia Disorder

  NCT06010693· Phase 3· Jiangsu Simcere Pharmaceutical Co., Ltd.· Source

• Completed

  A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia

  NCT05919823· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Completed

  A Preliminary Study of Model-driven Individualized Transcranial Electrical Stimulation for Insomnia

  NCT05445999· Shanghai Mental Health Center· Source

• Completed

  A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05550532· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Predictors of Functional Remission in Discharged Patients With Schizophrenia After Long-term Drug Discontinuation

  NCT05667961· Shanghai Mental Health Center· Source

• Completed

  A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects

  NCT05238701· Phase 1· Luye Pharma Group Ltd.· Source

• Completed

  Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

  NCT04846868· Phase 3· Boehringer Ingelheim· Source

• Completed

  Developing Dual-channel Transcranial Alternating Current Stimulations Targeting Negative Symptoms in Schizophrenia

  NCT04859504· Shanghai Mental Health Center· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Schizophrenia105 works · 26 trials
• Depression57 works · 15 trials
• Bipolar disorder22 works · 6 trials